Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients …
YH Chan, CY Chan, SW Chen, TF Chao, GYH Lip - Europace, 2023 - academic.oup.com
Aims Limited real-world data show that rivaroxaban following dosage criteria from either
ROCKET AF [20 mg/day or 15 mg/day if creatinine clearance (CrCl)< 50 mL/min] or J …
ROCKET AF [20 mg/day or 15 mg/day if creatinine clearance (CrCl)< 50 mL/min] or J …
A cross-sectional study of appropriateness evaluation of anticoagulation therapy for inpatients with nonvalvular atrial fibrillation
XY Zheng, GW Feng, J Guo, F Xie, X Li… - Frontiers in …, 2023 - frontiersin.org
Background: Oral anticoagulants (OACs) are essential for stroke prevention in patients with
nonvalvular atrial fibrillation (NVAF). However, the appropriateness of anticoagulation …
nonvalvular atrial fibrillation (NVAF). However, the appropriateness of anticoagulation …
Effectiveness and safety of early versus routine switching from low-molecular-weight heparin to maintenance therapy of rivaroxaban for acute iliofemoral vein …
W Hou, D Fang, S Yin, Y Deng, J Zhang, S Wang… - Annals of Vascular …, 2024 - Elsevier
Objectives The anticoagulation strategy of switching to rivaroxaban after one week of initial
low-molecular-weight heparin (LMWH) therapy is recommended by a guideline for the …
low-molecular-weight heparin (LMWH) therapy is recommended by a guideline for the …